Related Experiment Video
Updated: Jun 15, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Landscape phage ligands for PC3 prostate carcinoma cells
P K Jayanna1, D Bedi, P Deinnocentes
1Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Protein Engineering, Design & Selection : PEDS
|February 27, 2010
Summary
Researchers used phage display technology to identify novel peptide ligands targeting prostate cancer cells. These phage ligands show promise for developing targeted therapies and diagnostics for prostate carcinoma.
Area of Science:
- Nanobiotechnology
- Molecular Biology
- Oncology
Background:
- Targeting drugs to tumor receptors enhances efficacy.
- Phage display is a powerful tool for identifying specific molecular ligands.
- Phage nanobiotechnology enables the use of phage particles in nanomedicine.
Purpose of the Study:
- To identify phage ligands with specificity for PC3 prostate carcinoma cells.
- To explore the potential of these ligands in nanomedicine applications.
Main Methods:
- Utilized two landscape phage libraries for ligand selection.
- Employed a stringent selection scheme to isolate specific binders.
- Validated ligand specificity using target-association assays, microscopy, and flow cytometry.
Main Results:
- Identified three specific phage ligands: DTDSHVNL, DTPYDLTG, and DVVYALSDD.
- Demonstrated specificity and selectivity of these ligands for PC3 cells.
- Confirmed the utility of phage ligands and coat proteins as navigating modules.
Conclusions:
- The identified phage ligands are effective for targeting prostate carcinoma cells.
- These ligands can be utilized in developing novel therapeutic and diagnostic nanomedicines for prostate cancer.
